Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension

Hypertension Research

Volumn 34, Issue 4, 2011, Pages 509-515

  Fogari, Roberto ^a,b   Zoppi, Annalisa ^a   Salvadeo, Sibilla A T ^a   Mugellini, Amedeo ^a   Lazzari, Pierangelo ^a   Santoro, Tara ^a   Derosa, Giuseppe ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

candesartan; fibrinolysis; imidapril; insulin sensitivity

Indexed keywords

ANGIOTENSIN II; BRADYKININ; CANDESARTAN; DESMOPRESSIN; GLUCOSE; IMIDAPRIL; ISOPHANE INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; BODY WEIGHT; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG MECHANISM; FEMALE; FIBRINOLYSIS; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOLYSIS; HUMANS; HYPERTENSION; IMIDAZOLIDINES; INSULIN RESISTANCE; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; SINGLE-BLIND METHOD; TETRAZOLES; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79953680485     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.260     Document Type: Article

References (61)

1. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998; 32: 965-971. (Pubitemid 29001421)
2. Vaughan DE. Angiotensin, fibrinolysis and vascular homeostasis. Am J Cardiol 2001; 87(Suppl): 18C-24C.
3. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and pro-inflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98: 121-128. (Pubitemid 43902687)
4. Feener EP, Nortrup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor 1 and 2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995; 95: 1353-1362.
5. Nishimura H, Tsuji H, Masuda H, Nakagawa K, Nakahara Y, Kitamura H, Kasahara T, Sugano T, Yoshizumi M, Sawada S, Nakagawa M. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb Haemost 1997; 77: 1189-1195. (Pubitemid 27311993)
6. Olson JA, Shiverick KT, Ogilvie S, Buhi WC, Raizada MK. Angiotensin II induces secretion of plasminogen activator inhibitor 1 and a tissue metalloprotease inhibitor-related protein from rat brain astrocytes. Neurobiology 1991; 88: 1928-1932. (Pubitemid 21916340)
7. Van Leeuwen RT, Kol A, Andreotti F, Kluft C, Maseri A, Sperti G. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994; 90: 362-368. (Pubitemid 24203700)
8. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin-system and fibrinolytic function. Circulation 1993; 87: 1969-1973. (Pubitemid 23165641)
9. Brown NJ, Kim KS, Chen YQ, Blevins LS, Nadeau JH, Meranze SG, Vaughan DE. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor 1 production. J Clin Endocrinol Metab 2000; 85: 336-344. (Pubitemid 32268835)
10. Emeis JJ, Tranquille N. On the role of bradykinin in secretion from vascular endothelial cells. Agents Actions 1992; 38: 285-292.
11. Brown NJ, Gainer JV, Stein CM, Vaughan DE. Bradykinin stimulate tissue plasminogen activator release in human vasculature. Hypertension 1999; 33: 1431-1435. (Pubitemid 29282666)
12. Wright RA, Flapan AD, Alberti KG, Ludlam CA, Fox KA. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994; 24: 67-73. (Pubitemid 24202778)
13. Vaughan DE, Rouleau JL, Ridker PM, Arnold JM, Menapace FJ, Pfeffer MA. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction: HEART Study investigators. Circulation 1997; 96: 442-447. (Pubitemid 27329418)
14. Soejima H, Ogawa H, Yasue H, Suefuji H, Kaikita K, Nishiyama K. Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction. Clin Cardiol 1997; 20: 441-445. (Pubitemid 27184937)
15. Sayer JW, Gutteridge C, Syndercombe-Court D, Wilkinson P, Timmis AD. Circadian activity of the endogenous fibrinolytic system in stable coronary artery disease: effects of beta-adrenoreceptor blockers and angiotensin converting enzyme inhibitors. J Am Coll Cardiol 1998; 32: 1962-1968. (Pubitemid 29010462)
16. Sakata K, Shirotani M, Yoshida H, Urano T, Takada Y, Takada A. Differential effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension. Am Heart J 1999; 137: 1094-1099. (Pubitemid 30040734)
17. Fogari R, Preti P, Lazzari P, Corradi L, Zoppi A, Fogari E, Mugellini A. Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients. Eur J Clin Pharmacol 2003; 59: 271-275. (Pubitemid 37100344)
18. Vaughan DE, Rouleau JI, Pfeffer MA. Role of the fibrinolytic system in preventing myocardial infarction. Eur Heart J 1995; 16(Suppl K): 31-36. (Pubitemid 26031511)
19. Matsumoto T, Minai K, Horie H, Ohira N, Takashima H, Tarutani Y, Yasuda Y, Ozawa T, Matsuo S, Kinoshita M, Horie M. Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. J Am Coll Cardiol 2003; 41: 1373-1379. (Pubitemid 36438999)
20. Janson JH, Borman K, Nilsson TK. Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction. Eur J Clin Pharmacol 1993; 44: 485-488. (Pubitemid 23165002)
21. Lottermoser K, Wostmann B, Weisser B, Hertfelder HJ, Schmitz U, Vetter H, Dusing R. Effects of captopril on fibrinolytic function in healthy humans. Eur J Med Res 1999; 4: 31-34.
22. Trifiletti A, Barbera N, Scamardi R, Bagnato L, Pizzoleo MA, Nevoso A, Lasco A, Pedullà M, Frisina N. Effects of medium-term antihypertensive therapy on hemostatic parameters in patients with essential hypertension. Haemostasis 1997; 27: 35-38. (Pubitemid 27151711)
23. Alessi MC, Juhan-Vague I, Declerck PJ, Collen D. Molecular forms of plasminogen activator inhibitor 1 (PAI-1) and tissue type plasminogen activator (t-PA) in human plasma. Thromb Res 1991; 62: 275-285.
24. Hrafnkelsdottir T, Gudnason T, Wall U, Jern C, Jern S. Regulation of local availability of active tissue-type plasminogen activator in vivo in man. J Thromb Haemost 2004; 2: 1960-1968. (Pubitemid 40192750)
25. Giannarelli C, Virdis A, De Negri F, Duranti E, Magagna A, Ghiadoni L, Salvetti A, Taddei S. Tissue-type plasminogen activator release in healthy subjects and hypertensive patients. Relationship with beta-adrenergic receptors and the nitric oxide pathway. Hypertension 2008; 52: 314-321.
26. Lottermoser K, Hertfelder HH, Vetter H, Dusing R. Fibrinolytic function in diuretic-induced volume depletion. Am J Hypertens 2000; 13: 359-363. (Pubitemid 30312654)
27. Erdem Y, Usalan C, Haznedaroqlu IC, Altun B, Arici M, Yasavul U, Turgan C, Caglar S. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999; 11: 1071-1076.
28. Liu L, Zhao SP, Zhou HN, Li QZ, Li Jx. Effect of fluvastatin and valsartan, alone and in combination, on post-prandial vascular inflammation and fibrinolytic activity in patients with essential hypertension. J Cardiovasc Pharmacol 2007; 50: 50-55. (Pubitemid 47220446)
29. Seljeflot I, Moan A, Kjeldsen S, Sandvik E, Arnesen H. Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension. Hypertension 1996; 27: 1299-1304. (Pubitemid 26165634)
30. Fogari R, Zoppi A, Malamani G, Marasi G, Pesce RM, Banderali A, Mugellini A. Effects of four angiotensin II-receptor antagonists on fibrinolysis in post-menopausal women with hypertension. Curr Ther Res 2001; 62: 68-78. (Pubitemid 32493032)
31. Skurk T, Lee YM, Nicuta-Rolfs TO, Haastert B, Wirth A, Hauner H. Effect of the angiotensin II receptor blocker candesartan on fibrinolysis in patients with mild hypertension. Diabetes Obes Metab 2004; 6: 56-62. (Pubitemid 38159730)
32. Lin TH, Voon WC, Yen HW, Huang CH, Su HM, Lai WT, Sheu SH. Lercanidipine and losartan effects on blood pressure and fibrinolytic parameters. Kaohsiung J Med Sci 2006; 22: 177-183.
33. Brown NJ, Agirbasli M, Vaughan DE. Comparative effect of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 1999; 34: 285-290. (Pubitemid 29409229)
34. Goodfield NE, Newby DE, Ludlam CA, Flapan AD. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999; 99: 2983-2985. (Pubitemid 29270426)
35. Fogari R, Zoppi A, Preti P, Fogari E, Malamani G, Mugellini A. Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive post-menopausal women. Am J Hypertens 2001; 14: 921-926. (Pubitemid 32862593)
36. Fogari R, Mugellini A, Zoppi A, Corradi L, Preti P, Lazzari P, Derosa G. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetics. Am J Hypertens 2002; 15: 316-320. (Pubitemid 34408970)
37. Paterna S, Di Garbo V, Avellone G, Di Pasquale P, Cacia A, Tuttolomondo A, Follone G, Cardinale A, Maniscalchi T, Licata G. Effects of losartan and delapril on the fibrinolytic system in patients with mild to moderate hypertension. Clin Drug Invest 2003; 23: 717-724. (Pubitemid 37373793)
38. Hirschl MM, Bur A, Woisetschlaeger C, Derhaschnig U, Laggner AN. Effects of candesartan and lisinopril on the fibrinolytic system in hypertensive patients. J Clin Hypertens 2007; 9: 430-435.
39. Brummer EJP, Baret-Bergshoeff MM, Allen RA, Schicht I, Bertina RM, Schalekamp MADH. The use of desmopressin acetate (DDAVP) as a test of the fibrinolytic capacity. Analysis of responders and non responders. Thromb Haemost 1982; 48: 156.
40. Wall U, Jern S, Tengborn L, Jern C. Evidence of local mechanism for desmopressin-induced tissue-type plasminogen activator release in human forearm. Blood 1998; 91: 529-537. (Pubitemid 28053375)
41. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor by the human hepatocellular cell line HepG2. Thromb Haemost 1988; 60: 491-494. (Pubitemid 19023748)
42. Nordt TK, Klassen KJ, Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type 1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb 1993; 13: 1822-1828. (Pubitemid 23360569)
43. Nordt TK, Sawa H, Fujii S, Sobel BE. Induction of plasminogen activator inhibitor type -1(PAI-1) by proinsulin and insulin in vivo. Circulation 1995; 91: 764-770.
44. Juan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457-462.
45. Jeng JR, Sheu WHH, Jeng SC, Huang SH, Shieh SM. Impaired fibrinolysis and insulin resistance in patients with hypertension. Am J Hypertens 1996; 9: 484-490.
46. Juhan Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non-insulin dependent diabetic patients: Relationship with plasma insulin. Thromb Haemost 1989; 61: 370-373. (Pubitemid 19168139)
47. De Fronzo RA, Tobin JA, Andres B. Glucose clamp technique, a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: 214-223.
48. Hansson L, Hedner T, Dahlof B. Prospective, randomized, open, blinded end-point (PROBE) study: a novel design for intervention trials. Blood Press 1992; 1: 113-114.
49. Verheijen JH, Chang GTC, Kluff C. Evidence for the occurrence of a fast acting inhibitor of tissue-type plasminogen activator in plasma. Thromb Haemost 1984; 51: 392-395. (Pubitemid 14097900)
50. Brown NJ, Kumar S, Painter CA, Vaughan DE. ACE inhibition versus angiotensin type 1 receptor antagonism. Differential effects on PAI-1 over time. Hypertension 2002; 40: 859-865. (Pubitemid 35434907)
51. Folsom AR, Quamhieh DT, Wing RR, Jeffery RW, Stinson VL, Kuller LH, Wu KK. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII and other hemo-static factors in moderately overweight adults. Arterioscler Thromb Vasc Biol 1993; 13: 162-169. (Pubitemid 23056789)
52. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995; 96: 2515-2520.
53. Moeller I, Clune EF, Fennessy PA, Bingley JA, Albiston AL, Mendelsohn FA, Chai SY. Up-regulation of AT4 receptor levels in carotid arteries following balloon injury. Regul Pept 1999; 83: 25-30. (Pubitemid 29378362)
54. Vague P, Juhan Vague I, Aless MC, Badier C, Valadier J. Metformin decreases the high plasminogen activator inhibitor capacity, plasma insulin and triglycerides levels in non-diabetic obese subjects. Thromb Haemost 1987; 57: 326-328. (Pubitemid 18024534)
55. Fogari R, Zoppi A, Lazzari P, Preti P, Mugellini A, Corradi L, Lusardi P. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol 1998; 32: 616-620. (Pubitemid 28440963)
56. Moan A, Hoieggen A, Seljieflot I, Risanger T, Aenesen H, Kjeldsen SE. The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens 1996; 14: 1093-1097. (Pubitemid 26329286)
57. Laakso M, Karjalainen L, Lempiainen-Kuosa P. Effects of losartan on insulin sensitivity in hypertensive subjects. Hypertension 1996; 28: 392-396. (Pubitemid 26296040)
58. Lithell H, Pollare T, Berne C. Insulin sensitivity in newly detected hypertensive patient-s:influence of captopril and other antihypertensive agents on insulin sensitivity and related biological parameters. J Cardiovasc Pharmacol 1990; 15(Suppl 5): S46-S52. (Pubitemid 20159136)
59. Torlone E, Bolli GB. Angiotensin converting enzyme inhibition improves insulin sensitivity in type II diabetes mellitus. Arch Gerontol Geriatr 1991; 3(Suppl 2): 287-290.
60. Falkner B, Canessa M, Anzalone D. Effect of angiotensin converting enzyme inhibitor (lisinopril) on insulin sensitivity and sodium transport in mild hypertension. Am J Hypertens 1995; 8: 454-460.
61. Blood Pressure Lowering Treatment Trialist's Collaboration. Pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25: 951-958.